Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab monotherapy for relapsed or refractory multiple myeloma after exposure to three drug classes
2023-504273-21-00Phase 2Authorised
- Sponsor
- Fundación PETHEMA
- Start
- Sep 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elranatamab in multiple myeloma (MM), sponsored by Fundación PETHEMA. Primary endpoints: Study completion status and Complete response and undetectable measurable residual disease rate. Planned start Sep 2023; status: authorised.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-504273-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504273-21-00.